treatment-resistant depression
Articles tagged with “treatment-resistant depression”
Treatment-Resistant Depression: Recovery Is Possible
WebMD covers recovery from treatment-resistant depression. Here's what TRD recovery looks like and where low-dose ketamine fits into the treatment picture.
FDA Clears NRX-101 + TMS Combo for Severe Depression
The FDA has authorized NRx Pharmaceuticals to offer NRX-101 combined with TMS for severe depression — here's what it means for the ketamine treatment landscape.
9/11 Widow's Depression Breakthrough Highlights Ketamine
A 9/11 survivor's successful ketamine treatment for treatment-resistant depression offers hope and insights for trauma-related mental health care.
Boston Ketamine Clinics: A Window Into Real-World Use
CBS News spotlights Boston ketamine clinics treating mental health conditions. What real-world patient outcomes reveal about low-dose ketamine therapy.
What a Year of Experimental Depression Treatment Reveals
A Guardian journalist spent a year testing ketamine, TMS, and gut therapy for depression. Here's what their experience reveals about low-dose ketamine.
FDA Clears MIND1 Trial: NRX-101 Plus Robotic TMS for Suicidality
The FDA has cleared the MIND1 trial testing NRX-101 plus robotic TMS for suicidality in treatment-resistant depression. What it means for ketamine patients.
Esketamine Safety Protocols: What Clinicians Now Emphasize
A new clinical overview on esketamine nasal spray details REMS requirements, two-hour monitoring, and vitals tracking. Here's what it means for ketamine patients.
When to Switch or Stay: NMDA Therapy Discontinuation Rates
New analysis reveals why patients stop NMDA receptor antagonist therapy—and what discontinuation data means for low-dose ketamine monitoring and dosing decisions.
What Dropout Rates Reveal About NMDA Therapy Tolerability
New psychiatric guidance examines why patients stop NMDA antagonist therapy and what side effect data means for low-dose ketamine treatment decisions.
When Ketamine Side Effects Signal Time to Adjust Dose
New clinical analysis examines why patients stop NMDA antagonist therapy—and how smarter dose management may improve remission outcomes in TRD.
Faster TRD Remission Hinges on Measurement and Dose Timing
New analysis in Psychiatric Times shows that symptom tracking and rapid dose adjustment drive faster remission in TRD—here's what it means for ketamine care.
What Side Effect Data Tells Us About Ketamine Dosing
New analysis of NMDA receptor antagonist side effects in treatment-resistant depression underscores why dose optimization and early monitoring matter.
NMDA Antagonist Side Effects: What the Data Says
New clinical analysis examines why patients stop ketamine and esketamine treatment—and what smarter monitoring can do to keep them on track.
Why Clinicians Are Pushing Harder on TRD Goals
New clinical thinking on treatment-resistant depression pushes toward true remission, not just symptom reduction. Here's what it means for ketamine patients.
Ketamine Side Effects & When to Switch: New Clinical Guidance
New clinical guidance urges tracking PHQ-9 scores, monitoring side effects closely, and switching NMDA treatments sooner to reach remission faster.
Rethinking Treatment-Resistant Depression Care in 2026
New clinical perspectives on treatment-resistant depression push for true remission over symptom reduction. Here's what it means for ketamine patients.
NMDA Antagonist Side Effects: What the Data Now Shows
Psychiatric Times reviews side effect profiles and dropout rates for NMDA antagonists like ketamine. Here's what it means for low-dose ketamine patients.
Insurance Gaps in Ketamine Care — And One Fix
Most health insurers deny coverage for ketamine depression treatment in 2026. Here's what that means for patients and how access gaps are being bridged.
How Clinicians Choose TRD Treatments in 2026
New clinical guidance on treatment-resistant depression highlights how patient preference, speed of response, and functional outcomes shape ketamine treatment decisions.
Esketamine's Role in Treatment-Resistant Depression
A new clinical overview examines esketamine's place in TRD care, including patient selection, access barriers, and rapid-acting benefits for suicidal ideation.
Glutamate Pathway Treatments Reshape TRD Care in 2026
A 2026 review in Psychiatric Times highlights how esketamine and glutamate-targeting drugs are changing treatment-resistant depression care.
TRD Management: Why Remission Should Be the Goal
New clinical guidance on treatment-resistant depression urges full remission over symptom reduction — here's what it means for low-dose ketamine patients.
TRD Experts Push for Remission, Not Just Response
Psychiatrists are shifting TRD goals from symptom reduction to full remission. Here's what that means for ketamine patients and their treatment plans.
Treatment-Resistant Depression Algorithms: Where Ketamine Fits
Analysis of where ketamine fits within treatment-resistant depression algorithms, reviewing staging models, sequencing strategies, and evidence-based positioning in the TRD pathway.
Ketamine Maintenance Infusion Protocols: Frequency and Duration Optimization
How often are ketamine maintenance infusions given? Review of frequency, duration, tapering strategies, and long-term outcomes for sustained low-dose response.
Low-Dose Ketamine for Bipolar Depression: Efficacy and Safety Data
Comprehensive review of low-dose ketamine for bipolar depression, examining clinical trial efficacy, safety profiles, and rapid-acting antidepressant mechanisms in bipolar disorder.
Standard IV Ketamine Infusion Protocols for Treatment-Resistant Depression
How are IV ketamine infusions dosed for treatment-resistant depression? Review of 0.5 mg/kg standard, session structure, monitoring, and evidence base.
Meta-Analyses of Low-Dose Ketamine for Treatment-Resistant Depression
A comprehensive review of major meta-analyses examining the efficacy and safety of low-dose ketamine in treatment-resistant depression. This overview synthesizes findings across multiple systematic reviews to characterize effect sizes, response rates, and durability of antidepressant outcomes.
Patient Selection Criteria for Low-Dose Ketamine Therapy
Evidence-based patient selection criteria for low-dose ketamine therapy, covering indications, contraindications, risk-benefit assessment, and clinical decision-making frameworks.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.